東北メディカル・メガバンク機構

お知らせ

記事一覧
全て
ニュース
イベント
成果
メディア
2012.10.05

第14回インシリコ・メガバンク研究会開催のお知らせ(10月12日)

インシリコ・メガバンク研究会の第14回を10月12日(金)15時-16時から行いますのでご案内いたします。
geneXplainというソフトウェアを使ってどのようにして癌細胞に作用する薬の探索支援を行うかという話になります。

演者: Dr. Olga Kel
所属:Director Applied Life Science Informatics geneXplain GmbH

Title: How promoters help to find new drugs Mechanisms of action of RITA compound on cancer cells

Abstract:
The current study is done in collaboration between Karolinska Institute, Sweden, Institute of Biomedical Chemistry, Russia, and geneXplain GmbH, Germany, and partially funded by European commission in FP7 research project “Net2Drug”.

Background. Antineoplastic compound RITA is known to prevent p53-mdm2 interactions and thus to result in increasing levels of active p53.

High concentrations of RITA cause apoptosis in cancer cells, however small concentrations of RITA do not.

Aim of the study. To understand concentration- and time-dependent molecular  mechanisms of action of the antineoplastic compound RITA as well as to suggest novel candidate compounds to be applied in combination with small concentration of RITA, the following steps were done.

Initially, large scale gene expression and ChIP-seq studies were performed on breast cancer MCM7 cells treated with RITA in both high and small concentration.

At the next step, computational analysis with the geneXplain platform confirmed concentration- and time-dependent downregulation of pro-survival genes. Upstream analysis approach was applied to these genes. First, their promoters were analyzed and combinations of transcription factors involved in their regulation were identified. Next, topological modeling of the signal transduction network upstream of these transcription factors revealed potential master-regulators of the cell survival program that may prevent efficient apoptosis in cancer cells. We considered master regulatory proteins (e.g. PI3K subunits) as causal biomarkers as well as prospective targets for novel anticancer drug combinations.

Then, the cheminformatics program PASS was applied to the target molecules suggest at the previous step. We identified several novel prospective antineoplastic chemical compounds.

Finally, two compounds were experimentally validated in a cellular assay confirming their potential to selectively triggering apoptosis in cancer cells and act synergistically with small concentration of RITA.

概要

日 時 : 2012年10月12日(金)15:00-16:00

会 場 :東北大学星陵キャンパス 東北メディカル・メガバンク機構プレハブ棟2F会議室1

 

東北メディカル・メガバンク機構

お知らせ
2017.10.23| 三枝大輔講師らの執筆記事が日本質量分析学会の学会誌に掲載されました 2017.10.23| 第16回倫理・法令・社会連続セミナー(講師:及川正範先生(東京大学))を開催しました(9月4日) 2017.10.23| 卵巣明細胞癌に生じるゲノム異常に関する論文が掲載されました 2017.10.23| 山本雅之機構長・荻島創一准教授らが執筆した実験医学増刊号『ヒト疾患のデータベースとバイオバンク』が発行されました 2017.10.20| 熊本こころのケアセンター・熊本県精神保健福祉センターの皆さまがToMMoを来訪されました

Copyright(C) Tohoku University Tohoku Medical Megabank Organization All Rights Reserved.